Golden has been acquired by ComplyAdvantage.Read about it here ⟶

Cytodyn

Cytodyn is a company that develops treatments and therapies for people with infections and immune deficiency viruses

Overview Structured Data Issues Contributors Activity

All edits

Edits on 5 May, 2023

"Covert AngelList URL to Wellfound ID"

Golden AI

edited on 5 May, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Wellfound ID

cytodyn

Edits on 16 Mar, 2023

"prospector:2473:2561919"

Katrina-Kay Pettitt

edited on 16 Mar, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Biotechnology

"prospector:2472:2546715"

Katrina-Kay Pettitt

edited on 16 Mar, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Biology

Edits on 22 Feb, 2023

"prospector:2317:2474654"

Katrina-Kay Pettitt

edited on 22 Feb, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Technology

Edits on 19 Sep, 2022

"prospector:1906:1378156"

Katrina-Kay Pettitt

edited on 19 Sep, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Industry

Engineering

Edits on 17 Aug, 2022

Войдило Артур Игоревич

edited on 17 Aug, 2022

Edits made to:

Infobox (+1 properties)

Infobox

B2X

B2B

Edits on 31 Jul, 2022

Patrick Pum

edited on 31 Jul, 2022

Edits made to:

Infobox (+13/-2 properties)

Infobox

CIK number

1,175,6800

IRS number

753,056,2370

Location

Vancouver, Washington

SIC code

2,8340

Stock symbol

CYDY0

Industry

Place of incorporation

Colorado

NAICS code

325,4120

Board of Directors

Contact page URL

https://www.cytodyn.com/contact

DUNS Number

1173405760

Email address

info@cytodyn.com0

Fax number

+136079959540

Full address

1111 Main Street Suite 660 Vancouver, WA 98660 USA0

Phone number

+136098085240

Place of incorporation

Delaware

Previous name

CYTODYN INC0

REXRAY CORP0

Edits on 28 Jul, 2022

"remove blacklisted domain URLs"

Golden AI

edited on 28 Jul, 2022

Edits made to:

Article

Article

Cytodyn is a company that develops treatments and therapies for people with infections and immune deficiency viruses. The company was founded in 2002 in Lake Oswego, Oregon, United States.

...

The company is primarily interested in creating products and solutions to impact HIV and AIDS issues. The company's main pursuit is to develop a monoclonal antibody receptor antagonist that help prevent HIV, GVHD, NASH, and cancer from metastasizing on and using the CCR5 receptors as a gateway to healthy cells. The antibody is known as Leronlimab.

Edits on 20 May, 2022

"Edit from table cell"